Halda Therapeutics

Halda Therapeutics was a clinical-stage biotechnology company and Yale University spinout developing oral, targeted cancer therapies built on its proprietary RIPTAC (Regulated Induced Proximity TArgeting Chimera) platform, a novel "hold and kill" modality for the precision treatment of solid tumors. Its lead program, HLD-0915, is a first-in-class oral RIPTAC therapeutic in development for metastatic castration-resistant prostate cancer (mCRPC), with earlier-stage candidates spanning breast, lung, and other tumor types. Backed by investors including Canaan Partners, Halda was acquired by Johnson & Johnson in 2025 for approximately $3.05 billion in cash, with its platform folded into Johnson & Johnson Innovative Medicine's oncology pipeline. As a therapeutics developer, Halda operated no public developer platform, API, or documentation surface; this profile is maintained in the API Evangelist network as a company identity and portfolio-graph record rather than an API producer.

Halda Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Cancer Therapeutics.

🌐 Visit website 📡 Source on GitHub
2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyPharmaceuticalsOncologyCancer TherapeuticsProstate CancerDrug DiscoveryLife SciencesYale Spinout

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 2.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 0.0 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/halda-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

apis.yml Raw ↑ 
aid: halda-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/halda-therapeutics.png
name: Halda Therapeutics
description: Halda Therapeutics was a clinical-stage biotechnology company and Yale University spinout developing oral, targeted
  cancer therapies built on its proprietary RIPTAC (Regulated Induced Proximity TArgeting Chimera) platform, a novel "hold
  and kill" modality for the precision treatment of solid tumors. Its lead program, HLD-0915, is a first-in-class oral RIPTAC
  therapeutic in development for metastatic castration-resistant prostate cancer (mCRPC), with earlier-stage candidates spanning
  breast, lung, and other tumor types. Backed by investors including Canaan Partners, Halda was acquired by Johnson & Johnson
  in 2025 for approximately $3.05 billion in cash, with its platform folded into Johnson & Johnson Innovative Medicine's oncology
  pipeline. As a therapeutics developer, Halda operated no public developer platform, API, or documentation surface; this
  profile is maintained in the API Evangelist network as a company identity and portfolio-graph record rather than an API
  producer.
url: https://raw.githubusercontent.com/api-evangelist/halda-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: johnson-and-johnson
x-acquisition-value-usd: '3050000000'
x-acquisition-year: '2025'
x-industry: biotechnology
x-no-api-surface: 'true'
x-enrichment-note: 'Enrichment 2026-07-19: haldatx.com now redirects to jnj.com/innovativemedicine following the Johnson &
  Johnson acquisition. No public API, developer portal, documentation, SDK, or technical surface exists (searched). Identity-only
  enrichment; no API artifacts produced (no fabrication).'
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Cancer Therapeutics
- Prostate Cancer
- Drug Discovery
- Life Sciences
- Yale Spinout
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence